ENTA Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
14.4M
-16.3%
17.2M
-7.8%
18.6M
+23.1%
15.1M
-17.4%
18.3M
Cost of Revenue
0
0
0
0
0
Gross Profit
14.4M
-16.3%
17.2M
-7.8%
18.6M
+23.1%
15.1M
-17.4%
18.3M
Operating Expenses
31.6M
+8.9%
29.0M
-2.9%
29.9M
-10.9%
33.5M
-9.9%
37.2M
R&D
22.1M
+13.8%
19.4M
-6.8%
20.9M
-12.4%
23.8M
-12.5%
27.2M
SG&A
9.5M
-1.0%
9.6M
+6.2%
9.0M
-7.1%
9.7M
-3.0%
10.0M
Operating Income
-17236000
-45.4%
-11852000
-5.3%
-11253000
+38.8%
-18386000
+2.7%
-18893000
EBITDA
-16051000
-50.8%
-10643000
-6.2%
-10023000
+41.4%
-17102000
+3.3%
-17683000
Net Income
-19501000
-49.0%
-13091000
-9.7%
-11938000
+36.2%
-18700000
-2.4%
-18255000
EPS (Basic)
$-0.67
-48.9%
$-0.45
-7.1%
$-0.42
+51.7%
$-0.87
-2.4%
$-0.85
EPS (Diluted)
$-0.67
-48.9%
$-0.45
-7.1%
$-0.42
+51.7%
$-0.87
-2.4%
$-0.85
Shares (Diluted)
29.1M
+0.2%
29.0M
+1.0%
28.7M
+34.5%
21.4M
-0.0%
21.4M
Enanta Pharmaceuticals (ENTA) โ€” Financials